Research Laboratory of Novel Coronavirus Infection and Post-COVID Syndrome

Research Laboratory of Novel Coronavirus Infection and Post-COVID Syndrome

Head of Laboratory — Tatyana Karonova, MD, DSc, Associate Professor.

Major task

To search for clinical, laboratory, molecular and genetic predictors of development, severe course, outcomes and varying degrees of effectiveness of therapy for the new coronavirus infection (COVID-19).

Focus areas

  • Creating a single database of patients who have had a COVID-19 infection and a biobank of serum, plasma, DNA and pathological samples collected during the acute phase of the disease and in the post-COVID-19 phase.
  • Developing prognostic scales for assessing mortality in the acute phase of COVID-19.
  • Creating an optimal immunology panel to assess the severity and prognosis of COVID-19.
  • Conducting molecular genetic GWAS studies.
  • Studying the role of vitamin D in the pathogenesis, course and outcomes of COVID-19.
  • Analyzing structural and morphological changes in organs, including lungs, heart, central and peripheral nervous system, pancreas, thyroid, placenta, etc., in order to obtain data on the immunohistochemical characteristics of damaged tissues, the vascular bed, and the localization of the virus in cells.
  • Studying the predictors and development, course, spectrum of clinical manifestations, persistence and outcomes of cardiovascular, neurological, nephrological, affective disorders and endocrine dysfunction in patients during and after COVID-19.


A unified database is being created to include patients who had a new coronavirus disease caused by SARS-CoV-2 and were hospitalized to the infectious diseases hospital of Almazov Centre in the period from 2020 to 2021.

A collection of pathological samples has been obtained from COVID-19 patients for a detailed study of damage to certain organs and systems in severe cases of coronavirus disease.

Two clinical trials were initiated and completed to investigate the effects of vitamin D deficiency on the pathogenesis and course of COVID-19 and the possibility of using cholecalciferol to prevent SARS-CoV-2 infection in medical professionals and reduce the severity and improve prognosis in patients with acute COVID-19.

A complete examination was initiated for patients who have had COVID-19 in the past at various times in the post-COVID period.


  • Head of Laboratory — Tatyana Karonova, MD, DSc, Associate Professor.
  • Senior Researcher Maria Topuzova
  • Research Assistant Daria Lagutina
  • Research Assistant Arina Michailova

Major publications


Tatyana Karonova, Head of Laboratory